RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerN/A

Registered title, quoted from ClinicalTrials.gov

The Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive Models

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Zhongnan Hospital of Wuhan University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06768853, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. ECOG score 0-1;

    Inclusion criterion 5

  3. The interval between surgery and chest CT, lung function, and electrocardiogram examinations is less than or equal to 28 days;

    Inclusion criterion 10

  4. Pregnant/lactating women.

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06768853, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age range from 18 to 70 years old;
  • Chest CT shows a single pulmonary nodule, which may be adenocarcinoma or squamous cell carcinoma;
  • Chest CT shows multiple pulmonary nodules, but preoperative evaluation suggests that pulmonary nodules other than the main lesion are benign;
  • Preoperative auxiliary examination evaluates the patient as clinically resectable lung adenocarcinoma or squamous cell carcinoma in stages I, II, or IIIA (UICC-TNM 9th edition);
  • ECOG score 0-1;
  • Preoperative lung function FEV1 ≥ 1.0L and actual/expected value ≥ 80%;
  • No contraindications for surgery;
  • Technically, lobectomy or segmental resection combined with lymph node dissection can be performed;
  • Preoperative plain scan and enhanced chest CT examination;
  • The interval between surgery and chest CT, lung function, and electrocardiogram examinations is less than or equal to 28 days;
  • The patient signs a written informed consent form.

Exclusion Criteria:

  • Chest CT suggests multiple primary lung cancer or metastatic cancer;
  • Previous history of thoracic surgery;
  • Previous history of malignant tumors;
  • History of neoadjuvant therapy;
  • A history of severe heart failure, myocardial infarction, cerebral infarction, and pneumonia within 6 months prior to surgery;
  • Concurrent active bacterial or fungal infections;
  • Severe underlying lung diseases such as interstitial lung disease, pulmonary fibrosis, or emphysema are complicated;
  • Concomitant mental illness;
  • Pregnant/lactating women.

Quoted from ClinicalTrials.gov, NCT06768853, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06768853, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06768853